# Metabolic Solutions Development Co

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/metabolic-solutions-development-co

- Industry: Pharmaceuticals
- Headquarters: Kalamazoo, US
- Website: www.msdrx.com
- Latest round: Series B (Jan 8, 2008)
- Investors on record: 1

## About

Based in Michigan, US, and founded in 2006 by Chief Executive Officer Stephen Benoit, Metabolic Solutions Development Company LLC operates as a healthcare company providing insulin sensitizers, MSDC-0160 and MSDC-0602, mTOT modulators that lower glucose without the same degree of unwanted side effects such as fluid retention, weight gain, heart failure, edema, and bone loss. In January 2019, Metabolic Solutions Development Co LLC raised USD 0.20 million in venture debt financing. 

Metabolic Solutions Development Company LLC specializes in drug discovery and development focused on creating therapeutics for metabolic diseases linked to age-related mitochondrial dysfunction such as insulin resistance and type 2 diabetes. The company’s flagship products are its mTOT Modulators, including MSDC-0160 and MSDC-0602. These compounds are designed to improve insulin sensitivity by targeting the mitochondrial Target of Thiazolidinediones (mTOT) complex. It focuses on treating neurodegenerative diseases such as Alzheimer's and Parkinson's.

## Funding rounds

- Series B, Jan 8, 2008 — Hopen Life Science Ventures

## Investors

- Hopen Life Science Ventures (https://capitalatlas.ai/funds/hopen-life-science-ventures) — Series B